Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

NEUROTRANSMITTERS AND INTRAOCULAR PRESSURE

NEUROTRANSMITTERS AND INTRAOCULAR PRESSURE Summary— The role of the ocular autonomic nervous system in IOP regulation has been well established. Pharmacological and autohistoradiographic studies confirmed the high density of beta2 and alpha2 receptors on ciliary processes and iris epithelium. Their respective pharmacological activation or blockade is discussed. The role of other ocular neurotransmitters is also complex, as shown by the paradoxical similar action of dopamine agonists and antagonists on IOP. Concerning the cholinergic system, ocular muscarinic receptors are pharmacologically not well documented. Numerous other neurotransmitters may modulate IOP without necessarily leading to the development of new drugs. Drugs of the future will probably concentrate on dopaminergic agonists, cAMP‐stimulators such as forskolin, prostaglandins, and cannabinoids. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Fundamental & Clinical Pharmacology Wiley

NEUROTRANSMITTERS AND INTRAOCULAR PRESSURE

Loading next page...
 
/lp/wiley/neurotransmitters-and-intraocular-pressure-jWGIlVvqqQ

References (88)

Publisher
Wiley
Copyright
1988 Société Française de Pharmacologie et de Thérapeutique
ISSN
0767-3981
eISSN
1472-8206
DOI
10.1111/j.1472-8206.1988.tb00665.x
Publisher site
See Article on Publisher Site

Abstract

Summary— The role of the ocular autonomic nervous system in IOP regulation has been well established. Pharmacological and autohistoradiographic studies confirmed the high density of beta2 and alpha2 receptors on ciliary processes and iris epithelium. Their respective pharmacological activation or blockade is discussed. The role of other ocular neurotransmitters is also complex, as shown by the paradoxical similar action of dopamine agonists and antagonists on IOP. Concerning the cholinergic system, ocular muscarinic receptors are pharmacologically not well documented. Numerous other neurotransmitters may modulate IOP without necessarily leading to the development of new drugs. Drugs of the future will probably concentrate on dopaminergic agonists, cAMP‐stimulators such as forskolin, prostaglandins, and cannabinoids.

Journal

Fundamental & Clinical PharmacologyWiley

Published: Dec 1, 1988

There are no references for this article.